At the time of writing, Ionis Pharmaceuticals Inc [IONS] stock is trading at $30.71, up 3.02%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The IONS shares have gain 5.53% over the last week, with a monthly amount glided 1.79%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Ionis Pharmaceuticals Inc [NASDAQ: IONS] stock has seen the most recent analyst activity on April 07, 2025, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $45. Previously, Redburn Atlantic started tracking the stock with Neutral rating on March 31, 2025, and set its price target to $39. On August 02, 2024, downgrade downgraded it’s rating to Market Perform and revised its price target to $60 on the stock. Leerink Partners upgraded its rating to a Outperform and increased its price target to $62 on July 24, 2024. Bernstein upgraded its rating to Mkt Perform for this stock on June 14, 2024, but kept the price target unchanged to $44. In a note dated April 10, 2024, Wolfe Research upgraded an Outperform rating on this stock but restated the target price of $58.
For the past year, the stock price of Ionis Pharmaceuticals Inc fluctuated between $23.95 and $52.34. Currently, Wall Street analysts expect the stock to reach $51.68 within the next 12 months. Ionis Pharmaceuticals Inc [NASDAQ: IONS] shares were valued at $30.71 at the most recent close of the market. An investor can expect a potential return of 68.28% based on the average IONS price forecast.
Analyzing the IONS fundamentals
According to Ionis Pharmaceuticals Inc [NASDAQ:IONS], the company’s sales were 705.56M for trailing twelve months, which represents an -30.15% plunge. Gross Profit Margin for this corporation currently stands at 0.99% with Operating Profit Margin at -1.11%, Pretax Profit Margin comes in at -1.11%, and Net Profit Margin reading is -1.11%. To continue investigating profitability, this company’s Return on Assets is posted at -0.05, Equity is -1.23 and Total Capital is -0.06. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 2.96.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 29.77 points at the first support level, and at 28.82 for the second support level. However, for the 1st resistance point, the stock is sitting at 31.74, and for the 2nd resistance point, it is at 32.76.
Ratios To Look Out For
It is important to note that Ionis Pharmaceuticals Inc [NASDAQ:IONS] has a current ratio of 8.47. Also, the Quick Ratio is 8.43, while the Cash Ratio stands at 1.06. Considering the valuation of this stock, the price to sales ratio is 6.92, the price to book ratio is 8.24.
Transactions by insiders
Recent insider trading involved Birchler Brian, EVP, Corp and Development Ops, that happened on Apr 16 ’25 when 680.0 shares were sold. EVP, Chf GL Pdt Str Ofcr, Jenne Kyle completed a deal on Apr 16 ’25 to sell 3016.0 shares. Meanwhile, EVP, Chief Business Officer Baroldi Joseph sold 3928.0 shares on Apr 16 ’25.
